{
    "title": "115_hr4284",
    "content": "The \"Indexing Narcotics, Fentanyl, and Opioids Act of 2018\" or the \"INFO Act\" establishes a Substance Use Disorder Information Dashboard under Title XVII of the Public Health Service Act. The Secretary of Health and Human Services, in consultation with the Director of National Drug Control Policy, will establish a public information dashboard within 6 months of the enactment of the section. This dashboard will coordinate information on programs related to reducing opioid abuse and substance use disorders, provide access to data from various sources, and offer comparable data on substance use disorder. The section establishes a public information dashboard to coordinate programs for reducing opioid abuse and substance use disorders. It provides data on prevention and treatment strategies, recommendations for pain management alternatives, and guidelines for treating substance use disorders. The term 'controlled substance' is defined in accordance with the Controlled Substances Act. The Interagency Substance Use Disorder Coordinating Committee is established. The Secretary of Health and Human Services, in consultation with the Director of National Drug Control Policy, establishes the Interagency Substance Use Disorder Coordinating Committee to coordinate efforts within the Department of Health and Human Services regarding substance use disorder. Federal members of the Committee include the Secretary (Chair), the Attorney General, the Secretary of Labor, and the Secretary of Housing and Urban Development. The Interagency Substance Use Disorder Coordinating Committee includes representatives from various federal agencies such as the Secretary of Education, the Secretary of Veterans Affairs, the Commissioner of Social Security, and others. The Committee includes non-Federal members appointed by the Secretary, with specific requirements for individuals who have received treatment for opioid use disorder, substance use disorder, State Alcohol and Substance Abuse Directors, and representatives of research, advocacy, or organizations. The Committee includes non-Federal members appointed by the Secretary, with specific requirements for individuals who have received treatment for opioid use disorder, substance use disorder, State Alcohol and Substance Abuse Directors, and representatives of research, advocacy, or service organizations for adults with substance use disorder. Members must have relevant experience in treating individuals with opioid use disorder or other substance use disorders, with some members required to be employed with opioid treatment programs or have research experience in substance use disorder treatment. The Committee includes non-Federal members appointed by the Secretary, with specific requirements for individuals who have received treatment for opioid use disorder, substance use disorder, State Alcohol and Substance Abuse Directors, and representatives of research, advocacy, or service organizations for adults with substance use disorder. Members must have relevant experience in treating individuals with opioid use disorder or other substance use disorders, with some members required to be employed with opioid treatment programs or have research experience in substance use disorder treatment. The Committee also requires diverse expertise among its members, including professionals working with racial and ethnic minority populations, medically underserved populations, substance use disorder peer support specialists, drug court judges, and law enforcement or correctional officers with experience in interacting with adults with substance use disorder. The Committee appoints non-Federal members with specific requirements, including experience in treating opioid and substance use disorders. Members serve 3-year terms and vacancies are filled in the same manner as the original appointment. The Committee appoints non-Federal members with specific requirements, including experience in treating opioid and substance use disorders. Members serve 3-year terms and vacancies are filled in the same manner as the original appointment. The Committee shall meet not fewer than two times each year and monitor opioid use disorder and other substance use disorder research, services, and support activities across relevant Federal agencies. They also provide recommendations for improving Federal grants and programs for prevention, treatment, and recovery from opioid and substance use disorders. The Committee evaluates Federal substance use disorder prevention and treatment strategies, makes recommendations to the Secretary, and ensures public participation in decisions related to opioid and substance use disorders. They also provide recommendations for research, services, and prevention activities within the Department of Health. The Committee evaluates Federal substance use disorder prevention and treatment strategies, makes recommendations to the Secretary, and ensures public participation in decisions related to opioid and substance use disorders. They also provide recommendations for research, services, and prevention activities within the Department of Health. The Committee publishes an annual report summarizing its activities and may recommend extending its operations to Congress. The Committee may establish working groups to carry out duties and may continue after the termination date. The Federal Advisory Committee Act applies to the Committee, and it will terminate six years after establishment. The House of Representatives passed the bill on June 12, 2018. Karen L. Haas is the Clerk."
}